Tofacitinib for juvenile arthritis
Treatments studied
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial studies the use of a medication called tofacitinib in children and teenagers with juvenile idiopathic arthritis (JIA), a type of arthritis that starts in childhood. The goal is to see if the drug helps reduce joint pain and inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with juvenile idiopathic arthritis (JIA) by your doctor.
- Your doctor has decided that tofacitinib is a suitable treatment for your JIA.
- You are under 18 years old at the time the treatment is prescribed.
- Your arthritis is not caused by a recent infection (reactive arthritis), inflammatory bowel disease, or another autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study lets young people who benefited from filgotinib (a medication that reduces inflammation) in a previous trial continue taking it to see if it stays safe and effective over a longer period. It's designed for patients ages 8–17 who did well on this medicine before.
This trial tests whether tofacitinib (a pill that reduces inflammation) can help people with early-stage axial spondyloarthritis, a type of arthritis that mainly affects the spine and pelvis. It's for those who have had symptoms for 2 years or less and have active disease with signs of inflammation in MRI or blood tests.
This study is collecting real-world information about how Xeljanz (tofacitinib) is used and how well it works in children with juvenile idiopathic arthritis. It may help improve how the medicine is used safely in everyday care.
This Phase 3 trial studies how well upadacitinib (a pill) and tocilizumab (a shot/IV medicine) improve symptoms and inflammation in children with active systemic juvenile idiopathic arthritis (sJIA). It also looks at side effects and how these medicines move through the body.
This study tests different arthritis medications given in sequence for children and young adults with polyarticular JIA who did not get enough relief from a first TNF inhibitor. It aims to find which next treatment works best and is safe.
This trial tests whether the drug tofacitinib can help people with ALS by calming an overactive immune system. You’ll need a genetic test to see if your immune profile matches what the study is looking for.
Hear when a new Juvenile Idiopathic Arthritis (JIA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.